Stocktoria
PROCEPT BioRobotics Corp PRCT
PROCEPT BioRobotics Corp (PRCT) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $308.1M at a -31.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.84 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.757 |
| Retained earnings / assets | -1.263 |
| EBIT / assets | -0.204 |
| Equity / liabilities | 2.573 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PRCT | PROCEPT BioRobotics Corp | 3/9 | 2.18 | — | +37.2% |
| SKIN | SkinHealth Systems Inc. | 6/9 | -1.89 | — | -10% |
| ANGO | ANGIODYNAMICS INC | 5/9 | -1.82 | — | +9.5% |
| TCMD | TACTILE SYSTEMS TECHNOLOGY INC | 7/9 | 8.52 | 35.8 | +12.5% |
| LMAT | LEMAITRE VASCULAR INC | 6/9 | 8.18 | 37.9 | +13.5% |
| KIDS | ORTHOPEDIATRICS CORP | 4/9 | 2.67 | — | +15.4% |
| CERS | CERUS CORP | 4/9 | -13.54 | — | +16.1% |
About PROCEPT BioRobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
FAQ
Is PRCT financially healthy?
PROCEPT BioRobotics Corp's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does PRCT pay a dividend?
No, PROCEPT BioRobotics Corp does not currently pay a dividend.
How profitable is PRCT?
In FY2025, PROCEPT BioRobotics Corp had a net margin of -31.0% and a return on equity of -26.1%.
What is the analyst price target for PRCT?
The average Wall-Street price target for PROCEPT BioRobotics Corp is $30.20, about 42.1% above the recent price, from 10 analysts (consensus: buy).
Is PRCT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PROCEPT BioRobotics Corp: a Piotroski F-score of 3/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.